[1] MAJUMDER J, MINKO T. Recent developments on therapeutic and diagnostic approaches for COVID-19 [J]. AAPS J, 2021, 23(1):14.
[2] AMIN M. COVID-19 and the liver: overview [J]. Eur J Gastroenterol Hepatol, 2021, 33(3): 309-311.
[3] 车霄,王乐霄,赵磊,等. 重症新型冠状病毒肺炎患者的临床特征及预后风险因素分析[J].解放军医学院学报,2023,44(2): 101-107.
[4] PALLADINO M. Complete blood count alterations in COVID-19 patients: a narrative review[J]. Biochem Med: Zagreb, 2021,31(3):030501.
[5] ZHOU F, YU T, DU R H, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study[J]. Lancet, 2020, 395(10229): 1054-1062.
[6] HUANG C L, WANG Y M, LI X W, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China[J]. Lancet, 2020, 395(10223): 497-506.
[7] 中华人民共和国国家卫生健康委员会办公厅, 中华人民共和国国家中医药管理局综合司.新型冠状病毒感染诊疗方案(试行第十版)[J].中国医药,2023,18(2):161-166.
[8] 张金荣,闵翼,张建平,等. 苏州市637例感染新型冠状病毒奥密克戎变异株患者出院后88例核酸复检阳性病例特征分析 [J].临床肺科杂志,2023,28(3):340-344.
[9] CHEN Y Y, KLEIN S L, GARIBALDI B T, et al. Aging in COVID-19: vulnerability, immunity and intervention[J]. Ageing Res Rev, 2021, 65: 101205.
[10] LI H, LIU L, ZHANG D Y, et al. SARS-CoV-2 and viral sepsis: observations and hypotheses [J]. Lancet, 2020, 395(10235): 1517-1520.
[11] DOMINGUES R, LIPPI A, SETZ C, et al.SARS-CoV-2, immunosenescence and inflammaging: partners in the COVID-19 crime[J]. Aging: Albany NY, 2020, 12(18):18778-18789.
[12] 朱名超, 朱娅, 郭飞波, 等. 不同预后新型冠状病毒肺炎患者的临床和实验室特征分析[J]. 中华危重病急救医学,2020,32(12):1428-1433.
[13] 韩宁,杜凌遥,严丽波,等. 新型冠状病毒介导炎症反应的机制及治疗策略[J]. 生物医学工程学杂志,2020,37(4):572-578. |
